CD45R/B220 Rat anti-Mouse, Unlabeled, Clone: RA3-6B2, BD

Description

• The RA3-6B2 antibody reacts with an epitope on the extracellular domain of CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues
• It is expressed on B lyphocytes at all stages from pro-B through mature and activated B cell, but it is decreased on plasma cells and a subset of memory B cells
• Levels of expression of CD45R/B220 on the B-cell lineage appear to be developmentally regulated
• It is also found on the abnormal T cells involved in the lymphadenopathy of lpr/lpr and gld/gld mutant mice, on lytically active subsets of lymphokine-activated killer cells (NK cells and non-MHC-restricted CTL), on apoptotic T lymphocytes of mice injected with bacterial superantigen, on a population of NK-cell precursors in the bone marrow, and on B-lymphocyte, T-lymphocyte, and macrophage progenitors in fetal liver
• The CD45R/B220 antigen is not on hematopoietic stem cells, naive T lymphocytes, or MHC-restricted CTL
• CD45 is a member of the Protein Tyrosine Phosphatase (PTP) family: Its intracellular (COOH-terminal) region contains two PTP catalytic domains, and the extracellular region is highly variable due to alternative splicing of exons 4, 5, and 6 (designated A, B, and C, respectively), plus differing levels of glycosylation
• The CD45 isoforms detected in the mouse are cell type-, maturation, and activation state-specific
• The CD45 isoforms play complex roles in T-cell and B-cell antigen receptor signal transduction
• CD45R/B220 is commonly used as a pan B-cell marker; however, CD19 expression, detected by mAb 1D3, is reported to be more restricted to the B-cell lineage
• mAb RA3-6B2 has been reported to enhance isotype switching during in vitro B-cell responses and to inhibit in vivo B-cell responses
• Cross-reaction of RA3-6B2 mAb with activated human T lymphocytes has been observed
• This antibody is routinely tested by flow cytometric analysis
• Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.